Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie mające na celu ocenę zdarzeń niepożądanych, zmiany w aktywności choroby oraz sposobu, w jaki dożylnie podany ABBV-291 przemieszcza się po organizmie u dorosłych pacjentów chorych na chłoniaka nieziarniczego

25 września 2026 zaktualizowane przez: AbbVie

Pierwsze badanie fazy 1 na ludziach oceniające bezpieczeństwo, farmakokinetykę i skuteczność ABBV-291 w leczeniu chłoniaka nieziarniczego

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in adult participants in relapsed or refractory (R/R) NHL, including but not limited to diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Adverse events will be assessed.

ABBV-291 is an investigational drug being developed for the treatment of NHL. This study will include a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-291 and a dose expansion/optimization phase to determine the change in disease activity in participants with R/R NHL. Approximately 165 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide

In the dose escalation phase of the study participants will receive escalating Intravenously (IV) infused doses of ABBV-291, until the MAD/MTD is determined. In the dose expansion/optimization phase of the study participants receive IV infused ABBV-291, as part of the approximately 74 month study duration.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.

Przegląd badań

Status

Aktywny, nie rekrutujący

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

21

Faza

  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Victoria
      • Fitzroy Melbourne, Victoria, Australia, 3065
        • St Vincent's Hospital Melbourne /ID# 261664
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Sir Charles Gairdner Hospital /ID# 268579
    • Jerusalem
      • Jerusalem, Jerusalem, Izrael, 91120
        • Hadassah Medical Center-Hebrew University /ID# 261658
    • Tel Aviv
      • Tel Aviv, Tel Aviv, Izrael, 6423906
        • Tel Aviv Sourasky Medical Center /ID# 261659
    • Aichi-ken
      • Nagoya, Aichi-ken, Japonia, 464-8681
        • Aichi Cancer Center /ID# 267471
    • Chiba
      • Kashiwa-shi, Chiba, Japonia, 277-8577
        • National Cancer Center Hospital East /ID# 261775
    • Tokyo
      • Koto-ku, Tokyo, Japonia, 135-8550
        • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 267470
    • North Carolina
      • Huntersville, North Carolina, Stany Zjednoczone, 28078
        • Carolina BioOncology Institute /ID# 265259
    • Oregon
      • Eugene, Oregon, Stany Zjednoczone, 97401
        • Willamette Valley Cancer Institute and Research Center /ID# 270945
    • Texas
      • Austin, Texas, Stany Zjednoczone, 78705
        • Texas Oncology - Central/South Texas /ID# 270946
    • Utah
      • West Valley City, Utah, Stany Zjednoczone, 84119-3602
        • START Mountain Region /ID# 267592
    • Virginia
      • Fairfax, Virginia, Stany Zjednoczone, 22031
        • Virginia Cancer Specialists - Fairfax /ID# 265082
      • Manchester, Zjednoczone Królestwo, M20 4BX
        • The Christie /ID# 267177
      • Plymouth, Zjednoczone Królestwo, PL6 5FP
        • University Hospitals Plymouth NHS Trust /ID# 267174

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • For dose escalation (Part 1) only: Participants must have documented diagnosis of B-cell malignancies including (but not limited to) the following, with histology based on criteria established by the World Health Organization (WHO), and measurable disease requiring treatment:

    • Mantle cell lymphoma (MCL);
    • Marginal zone lymphoma (MZL);
    • Waldenstrom macroglobulinemia (WM);
    • Diffuse large b-cell lymphoma (DLBCL) (including: germinal center B-cell type, activated B-cell type, primary cutaneous DLBCL [leg type], Epstein-Barr virus-positive (EBV+) DLBCL [not otherwise specified], DLBCL associated with chronic inflammation, human herpesvirus 8-positive [HHV8+] DLBCL [not otherwise specified], B cell lymphoma [unclassifiable] with features intermediate between DLBCL and classical Hodgkin lymphoma, high-grade B-cell lymphoma [not otherwise specified], high-grade B-cell lymphoma [with MYC (avian myelocytomatosis viral oncogene homolog) and BCL2 and/or BCL6 rearrangements], DLBCL arising from follicular lymphoma [FL] [transformed FL]);
    • FL Grades 1 to 3B;
  • For dose expansion (Part 2) only: Participants must have documented diagnosis of one of the following B-cell malignancies, with histology based on criteria established by the WHO, and measurable disease requiring treatment:

    • Part 2a only: DLBCL (including: germinal center B-cell type, activated B-cell type, primary cutaneous DLBCL [leg type], EBV+ DLBCL [not otherwise specified], DLBCL associated with chronic inflammation, HHV8+ DLBCL [not otherwise specified], B-cell lymphoma [unclassifiable] with features intermediate between DLBCL and classical Hodgkin lymphoma, high-grade B-cell lymphoma [not otherwise specified], high-grade B-cell lymphoma [with MYC and BCL2 and/or BCL6 rearrangements], DLBCL arising from FL [transformed FL]);
    • Part 2b only: FL Grades 1 to 3B;
    • Part 2c only: Mantle cell lymphoma;
  • For all participants (Parts 1 and 2):

    • Must be considered relapsed or refractory to, or intolerant of, at least 2 or more prior lines of therapy known to provide a clinical benefit for their condition, and for whom there is no appropriate locally available therapy known to provide clinical benefit (e.g., standard chemotherapy or autologous stem cell transplantation [ASCT]).

    • Indolent non-Hodkin's lymphoma (NHL) participants must meet relevant disease specific requirements for treatment (e.g., National Comprehensive Cancer Network [NCCN], Groupe d'Etude des Lymphomes Folliculaires [GELF]).

    • History of allogeneic stem cell transplantation must be stable off of immunosuppression for at least 3 months.

    • For participants enrolled in backfill cohorts or at dose levels previously cleared, subjects must provide consent to an on-treatment fresh tumor biopsy from the same tumor lesion as the baseline tumor tissue. This requirement may be waived at the discretion of the contract research organization (CRO) Medical Monitor if collecting a biopsy would place the subject at risk of harm or would require a technically complicated procedure based on tumor location as assessed by the investigator or could hinder a subject's ability to participate in the study.

    • Previously treated with a CD79b-targeting therapy (e.g., CD79b monoclonal antibody) a core or excision tumor biopsy subsequent to the most recent CD79b-targeting therapy must be collected. Tumor biopsy requirements may be modified by Sponsor during the study. This requirement may be waived at the discretion of the contract research organization (CRO) Medical Monitor if collecting a biopsy would place the subject at risk of harm or would require a technically complicated procedure based on tumor location as assessed by the investigator or could hinder a subject's ability to participate in the study.

      • CD79b expression status will be assessed in all participants.
  • Have an eastern cooperative oncology group (ECOG) Performance Status of 0 or 1.

  • Laboratory values meeting the criteria in the protocol within the screening period prior to the first dose of study drug (if multiple samples are drawn within the screening period, the sample/result immediately prior to Cycle 1 Day 1 is applicable).

  • Availability of representative baseline tumor tissue (most recent archived tumor tissue or fresh biopsy collected during screening phase) suitable for immunohistochemistry (IHC) testing. This requirement may be waived at the discretion of the CRO Medical Monitor if collecting a biopsy at screening would place the participant at risk of harm or would require a technically complicated procedure based on tumor location as assessed by the investigator or could hinder a participant's ability to participate in the study.

Exclusion Criteria:

  • History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis.

  • Treatment with any of the following:

    • Anticancer therapy including chemotherapy, radiotherapy, small molecule, investigational, and biologic agents within 14 days (or at least 5 half-lives, whichever is shorter), prior to the first dose of the study treatment;
    • CD79b-directed agents (e.g., CD79b monoclonal antibody therapy) within 4 weeks (or at least 5 half-lives, whichever is shorter) prior to the first dose of study treatment.
    • Prior treatment with an antibody drug conjugate that consists of a topoisomerase I inhibitor.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nielosowe
  • Model interwencyjny: Zadanie sekwencyjne
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Escalation: Non-Hodgkin Lymphoma (NHL) ABBV-291

Participants with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), except chronic lymphocytic leukemia (CLL), will receive escalating doses of ABBV-291, as part of the 74 month study duration.

Intravenous Infusion

Eksperymentalny: Expansion: Diffuse Large B-Cell Lymphoma (DLBCL) ABBV-291

Participants with R/R DLBCL will receive the recommended Phase 1 expansion dose (RP1ED) of ABBV-291, as part of the 74 month study duration.

Intravenous Infusion

Eksperymentalny: Expansion: Follicular Lymphoma (FL) ABBV-291

Participants with R/R FL will receive the RP1ED of ABBV-291, as part of the 74 month study duration.

Intravenous Infusion

Eksperymentalny: Optimization: Mantle Cell Lymphoma (MCL) ABBV-291 Dose A

Participants with R/R MCL will receive the dose A of ABBV-291, as part of the 74 month study duration.

Intravenous Infusion

Eksperymentalny: Optimization: MCL ABBV-291 Dose B

Participants with R/R MCL will receive the dose B of ABBV-291, as part of the 74 month study duration.

Intravenous Infusion

Eksperymentalny: Optimization: MCL ABBV-291 Dose C

Participants with R/R MCL will receive the dose C of ABBV-291, as part of the 74 month study duration.

Intravenous Infusion

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants with Adverse Events (AE)s
Ramy czasowe: Up to 74 Months

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment.

Up to 74 Months
Percentage of Participants with Dose Limiting Toxicities (DLT)s
Ramy czasowe: Up to 74 Months

DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

Up to 74 Months
Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, and Hematology)
Ramy czasowe: Up to 74 Months

Percentage of participants with clinically significant laboratory values (chemistry, and hematology).

Up to 74 Months
Percentage of Participants with Clinically Significant Vital Sign Measurements
Ramy czasowe: Up to 74 Months

Vital sign are defined as determinations of systolic and diastolic blood pressure, pulse rate, respiratory rate, and body temperature.

Up to 74 Months
Percentage of Participants with Clinically Significant Electrocardiogram (ECG) Findings
Ramy czasowe: Up to 74 Months

Percentage of participants with clinically significant ECG findings.

Up to 74 Months
Objective Response Rate (ORR)
Ramy czasowe: Up to 74 Months

ORR is defined as the percentage of participants with a confirmed best overall response (BOR) of partial response (PR) or better per disease-specific response criteria (e.g., Lugano classification).

Up to 74 Months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Duration of Response (DOR) as Assessed by Investigator
Ramy czasowe: Up to 74 Months

DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to disease-specific response criteria to disease progression or death of any cause, whichever occurs earlier.

Up to 74 Months
Progression-Free Survival (PFS) as Assessed by Investigator
Ramy czasowe: Up to 74 Months

PFS is defined as time from first study treatment to a documented disease progression according to disease-specific response criteria, as determined by the investigator, or death due to any cause, whichever occurs earlier.

Up to 74 Months
Time to response (TTR)
Ramy czasowe: Up to 74 Months

TTR is defined as time from first study treatment to the initial response of PR (or better) per investigator review according to disease-specific response criteria.

Up to 74 Months
Area Under the Curve (AUC) of ABBV-291
Ramy czasowe: Up to 12 Months

AUC is defined as the area under the plasma/serum concentration-time curve of ABBV-291.

Up to 12 Months
Maximum Observed Plasma/Serum Concentration (Cmax) of ABBV-291
Ramy czasowe: Up to 12 Months

Cmax is defined as maximum observed plasma/serum concentration of ABBV-291.

Up to 12 Months
Time to Cmax (Tmax) of ABBV-291
Ramy czasowe: Up to 12 Months

Tmax is defined as time to Cmax of ABBV-291.

Up to 12 Months
Half-Life (t1/2) of ABBV-291
Ramy czasowe: Up to 12 Months

t1/2 is defined as the half-life of ABBV-291.

Up to 12 Months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Dyrektor Studium: ABBVIE INC., AbbVie

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

16 stycznia 2025

Zakończenie podstawowe (Szacowany)

1 stycznia 2027

Ukończenie studiów (Szacowany)

1 listopada 2031

Daty rejestracji na studia

Pierwszy przesłany

30 października 2024

Pierwszy przesłany, który spełnia kryteria kontroli jakości

30 października 2024

Pierwszy wysłany (Rzeczywisty)

31 października 2024

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

29 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

25 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

produkt wyprodukowany i wyeksportowany z USA

Tak

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj